Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria.
Huseby DL, Cao S, Zamaratski E, Sooriyaarachchi S, Ahmad S, Bergfors T, Krasnova L, Pelss J, Ikaunieks M, Loza E, Katkevics M, Bobileva O, Cirule H, Gukalova B, Grinberga S, Backlund M, Simoff I, Leber AT, Berruga-Fernández T, Antonov D, Konda VR, Lindström S, Olanders G, Brandt P, Baranczewski P, Vingsbo Lundberg C, Liepinsh E, Suna E, Jones TA, Mowbray SL, Hughes D, Karlén A.
Huseby DL, et al. Among authors: loza e.
Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2317274121. doi: 10.1073/pnas.2317274121. Epub 2024 Apr 5.
Proc Natl Acad Sci U S A. 2024.
PMID: 38579010
Free PMC article.